Search

Your search keyword '"Banys-Paluchowski, Maggie"' showing total 359 results
Start Over Author "Banys-Paluchowski, Maggie"
359 results on '"Banys-Paluchowski, Maggie"'

2. Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference—a German expert perspective

Author

Krug, David, Banys-Paluchowski, Maggie, Brucker, Sara Y., Denkert, Carsten, Ditsch, Nina, Fasching, Peter A., Haidinger, Renate, Harbeck, Nadia, Heil, Jörg, Huober, Jens, Jackisch, Christian, Janni, Wolfgang, Kolberg, Hans-Christian, Loibl, Sibylle, Lüftner, Diana, van Mackelenbergh, Marion, Radosa, Julia C., Reimer, Toralf, Welslau, Manfred, Würstlein, Rachel, Untch, Michael, and Budach, Wilfried

Published
2024
Full Text
View/download PDF

5. Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study

Author

Montagna, Giacomo, Laws, Alison, Ferrucci, Massimo, Mrdutt, Mary M., Sun, Susie X., Bademler, Suleyman, Balbaloglu, Hakan, Balint-Lahat, Nora, Banys-Paluchowski, Maggie, Barrio, Andrea V., Benson, John, Bese, Nuran, Boughey, Judy C., Boyle, Marissa K., Diego, Emilia J., Eden, Claire, Eller, Ruth, Goldschmidt, Maite, Hlavin, Callie, Heidinger, Martin, Jelinska, Justyna, Karadeniz Cakmak, Güldeniz, Kesmodel, Susan B., King, Tari A., Kuerer, Henry M., Loesch, Julie, Milardi, Francesco, Murawa, Dawid, Moo, Tracy-Ann, Menes, Tehillah S., Passeri, Daniele, Pastoriza, Jessica M., Perhavec, Andraz, Pislar, Nina, Polidorio, Natália, Rami, Avina, Ryu, Jai Min, Schulz, Alexandra, Sevilimedu, Varadan, Ugurlu, M. Umit, Uras, Cihan, van Hemert, Annemiek, Wong, Stephanie M., Yoo, Tae-Kyung Robyn, Zhang, Jennifer Q., Karanlik, Hasan, Cabioğlu, Neslihan, Peeters, Marie-Jeanne Vrancken, Morrow, Monica, Weber, Walter P., Ahn, Sung Gwe, Andreozzi, Mariacarla, Barbalho, Daniel Meirelles, Boileau, Jean François, Brogi, Edi, Cabero, Flavia Vidal, Cocco, Daniela, Corsi, Fabio, Crown, Angelena, de Bree, Eelco, del Mar Vernet-Tomas, Maria, Deutschmann, Christine, Ditsch, Nina, Esposito, Emanuela, Fayanju, Oluwadamilola M., Fick, Franziska, Fitzal, Florian, Flanagan, Meghan R., Gentile, Damiano, Gentilini, Oreste D., Grabenstetter, Anne, Gulcelik, Mehmet Ali, Heil, Jörg, Holtschmidt, Johannes, Krawczyk, Natalia, Kühn, Thorsten, Kümmel, Sherko, Leo, Cornelia, Muslumanoglu, Mahmut, Nekljudova, Valentina, Newman, Lisa A., Pilewskie, Melissa L., Poulakaki, Fiorita, Riedel, Fabian, Rocco, Nicola, Schnabel, Freya R., Schwartz, Christopher, Siegel, Emily L., Simonson, Colin, Singer, Christian, Soares, Leonardo Ribeiro, Christina Tampaki, Ekaterini, Tampakis, Athanasios, Tasoulis, Marios Konstantinos, Tausch, Christoph, Urban, Cicero, Van den Bruele, Astrid Botty, Vergauwen, Glenn, Vorburger, Denise, Wärnberg, Fredrik, Weiss, Anna, Williams, Austin D., Wimmer, Kerstin, Woodward, Steven G., and Ziauddin, Firdos M.

Published
2024
Full Text
View/download PDF

6. Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment: A New Concept

Author

Pfob, André, Cai, Lie, Schneeweiss, Andreas, Rauch, Geraldine, Thomas, Bettina, Schaefgen, Benedikt, Kuemmel, Sherko, Reimer, Toralf, Hahn, Markus, Thill, Marc, Blohmer, Jens-Uwe, Hackmann, John, Malter, Wolfram, Bekes, Inga, Friedrichs, Kay, Wojcinski, Sebastian, Joos, Sylvie, Paepke, Stefan, Degenhardt, Tom, Rom, Joachim, Rody, Achim, van Mackelenbergh, Marion, Banys-Paluchowski, Maggie, Große, Regina, Reinisch, Mattea, Karsten, Maria Margarete, Sidey-Gibbons, Chris, Wallwiener, Markus, Golatta, Michael, and Heil, Joerg

Published
2024
Full Text
View/download PDF

7. Seltene Malignome der Brust

Author

Pervan, Mascha, Princk, Henriette, Meneder, Sabine, Banys-Paluchowski, Maggie, Fehm, Tanja, Ruckhäberle, Eugen, Hanker, Lars, Fitzgerald, Sophia, Rody, Achim, and Krawczyk, Natalia

Published
2024
Full Text
View/download PDF

10. Applicability of magnetic seeds for target lymph node biopsy after neoadjuvant chemotherapy in initially node-positive breast cancer patients: data from the AXSANA study

Author

Hartmann, Steffi, Banys-Paluchowski, Maggie, Stickeler, Elmar, de Boniface, Jana, Gentilini, Oreste Davide, Kontos, Michalis, Seitz, Stephan, Kaltenecker, Gabriele, Wärnberg, Fredrik, Zetterlund, Linda Holmstrand, Kolberg, Hans-Christian, Fröhlich, Sarah, and Kühn, Thorsten

Published
2023
Full Text
View/download PDF

14. ASO Visual Abstract: Minimally-Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment—A New Concept

Author

Pfob, André, Cai, Lie, Schneeweiss, Andreas, Rauch, Geraldine, Thomas, Bettina, Schaefgen, Benedikt, Kuemmel, Sherko, Reimer, Toralf, Hahn, Markus, Thill, Marc, Blohmer, Jens-Uwe, Hackmann, John, Malter, Wolfram, Bekes, Inga, Friedrichs, Kay, Wojcinski, Sebastian, Joos, Sylvie, Paepke, Stefan, Degenhardt, Tom, Rom, Joachim, Rody, Achim, van Mackelenbergh, Marion, Banys-Paluchowski, Maggie, Große, Regina, Reinisch, Mattea, Karsten, Maria Margarete, Sidey-Gibbons, Chris, Wallwiener, Markus, Golatta, Michael, and Heil, Joerg

Published
2024
Full Text
View/download PDF

22. Idiopathic Granulomatous Mastitis as a Benign Condition Mimicking Inflammatory Breast Cancer: Current Status, Knowledge Gaps and Rationale for the GRAMAREG Study (EUBREAST-15).

Author

Krawczyk, Natalia, Kühn, Thorsten, Ditsch, Nina, Hartmann, Steffi, Gentilini, Oreste Davide, Lebeau, Annette, de Boniface, Jana, Hahn, Markus, Çakmak, Güldeniz Karadeniz, Alipour, Sadaf, Bjelic-Radisic, Vesna, Kolberg, Hans-Christian, Reimer, Toralf, Gasparri, Maria Luisa, Tauber, Nikolas, Neubacher, Melissa, and Banys-Paluchowski, Maggie

Subjects
MASTITIS diagnosis, STEROID drugs, MAMMOGRAMS, HEALTH literacy, BIOPSY, NONSTEROIDAL anti-inflammatory agents, INFLAMMATORY mediators, HEALTH status indicators, IMMUNOSUPPRESSIVE agents, BREAST tumors, METHOTREXATE, MASTITIS, IMMUNOSUPPRESSION, BREAST
Abstract

Simple Summary: Idiopathic granulomatous mastitis (IGM) is a rare breast disease that can be mistaken for inflammatory breast cancer. It requires a tissue biopsy for an accurate diagnosis. Even though it is not cancerous, IGM can cause emotional distress because of severe pain and ensuing breast deformity. It is important to distinguish IGM from other breast inflammations caused by infections. IGM is mostly found in premenopausal women, often after pregnancy or breastfeeding. Smoking and contraceptive use might be risk factors, but the evidence is unclear. The treatment options include NSAIDs, steroids, immunosuppressants, surgery, prolactin suppressants, and antibiotics; many patients relapse, making treatment challenging. This review summarizes current information, which mostly comes from case reports and small studies, and presents GRAMAREG as a registry for IGM initiated by the EUBREAST Study Group, which aims to collect detailed data on IGM to improve the knowledge base for diagnosis and treatment. Background: Idiopathic granulomatous mastitis (IGM) is a rare, benign inflammatory breast condition often mistaken for inflammatory breast cancer and, therefore, requires a biopsy for accurate diagnosis. Although not cancerous, IGM can cause emotional distress because of severe pain and ensuing breast deformity. Differentiating IGM from other breast inflammations caused by infections is essential. IGM mostly affects premenopausal women and is potentially associated with recent pregnancies and breastfeeding. The risk factors, including smoking and contraceptive use, have inconsistent associations. Steroid responses suggest an autoimmune component, though specific markers are lacking. Methods: We performed a narrative review on potential risk factors, diagnostics, and therapy of IGM. Results: Diagnostics and clinical management of IGM are challenging. The treatment options include NSAIDs, steroids, surgery, antibiotics, immunosuppressants, prolactin suppressants, and observation, each with varying effectiveness and side effects. Conclusions: Current IGM treatment evidence is limited, based on case reports and small series. There is no consensus on the optimal management strategy for this disease. The GRAMAREG study by the EUBREAST Study Group aims to collect comprehensive data on IGM to improve diagnostic and treatment guidelines. By enrolling patients with confirmed IGM, the study seeks to develop evidence-based recommendations, enhancing patient care and understanding of this condition. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Update Breast Cancer 2024 Part 1 – Expert Opinion on Advanced Breast Cancer

Author

Würstlein, Rachel, additional, Kolberg, Hans-Christian, additional, Hartkopf, Andreas D., additional, Fehm, Tanja N., additional, Welslau, Manfred, additional, Schütz, Florian, additional, Fasching, Peter A., additional, Janni, Wolfgang, additional, Witzel, Isabell, additional, Thomssen, Christoph, additional, Krückel, Annika, additional, Belleville, Erik, additional, Lüftner, Diana, additional, Untch, Michael, additional, Thill, Marc, additional, Hörner, Manuel, additional, Tesch, Hans, additional, Ditsch, Nina, additional, Lux, Michael P., additional, Aktas, Bahriye, additional, Banys-Paluchowski, Maggie, additional, Taran, Florin-Andrei, additional, Wöckel, Achim, additional, Harbeck, Nadia, additional, Stickeler, Elmar, additional, Bartsch, Rupert, additional, Schneeweiss, Andreas, additional, Ettl, Johannes, additional, Krug, David, additional, and Müller, Volkmar, additional

Published
2024
Full Text
View/download PDF

26. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024

Author

Thill, Marc, primary, Janni, Wolfgang, additional, Albert, Ute-Susann, additional, Banys-Paluchowski, Maggie, additional, Bauerfeind, Ingo, additional, Blohmer, Jens, additional, Budach, Wilfried, additional, Dall, Peter, additional, Ditsch, Nina, additional, Fallenberg, Eva Maria, additional, Fasching, Peter A., additional, Fehm, Tanja, additional, Friedrich, Michael, additional, Gerber, Bernd, additional, Gluz, Oleg, additional, Harbeck, Nadia, additional, Hartkopf, Andreas, additional, Heil, Jörg, additional, Huober, Jens, additional, Jackisch, Christian, additional, Kolberg-Liedtke, Cornelia, additional, Kreipe, Hans-Heinrich, additional, Krug, David, additional, Kühn, Thorsten, additional, Kümmel, Sherko, additional, Loibl, Sibylle, additional, Lüftner, Diana, additional, Lux, Michael Patrick, additional, Maass, Nicolai, additional, Mundhenke, Christoph, additional, Reimer, Toralf, additional, Rhiem, Kerstin, additional, Rody, Achim, additional, Schmidt, Marcus, additional, Schneeweiss, Andreas, additional, Schütz, Florian, additional, Sinn, Hans-Peter, additional, Solbach, Christine, additional, Solomayer, Erich-Franz, additional, Stickeler, Elmar, additional, Thomssen, Christoph, additional, Untch, Michael, additional, Witzel, Isabell, additional, Wöckel, Achim, additional, Würstlein, Rachel, additional, Müller, Volkmar, additional, and Park-Simon, Tjoung-Won, additional

Published
2024
Full Text
View/download PDF

31. Adressen

Author

Fehm, Tanja, primary, Aktas, Bahriye, additional, Banys-Paluchowski, Maggie, additional, Wimberger, Pauline, additional, Schmalfeldt, Barbara, additional, Beyer, Ines, additional, Borgmeier, Felix, additional, Briest, Susanne, additional, Burghardt, Bettina, additional, Dornhöfer, Nadja, additional, Fleitmann, Ann Kristin, additional, Gantert, Daniel, additional, Goeckenjan, Maren, additional, Heihoff-Klose, Anne, additional, Helbig, Martina, additional, Hirchenhain, Christine, additional, Hoffmann, Jürgen, additional, Krawczyk, Natalia, additional, Kyvernitakis, Ioannis, additional, Maul, Holger, additional, Meusel, Marcus, additional, Mickan, Franziska, additional, Naumann, Gert, additional, Paluchowski, Peter, additional, Ruckhäberle, Eugen, additional, Schrey-Petersen, Susanne, additional, Tauscher, Anne, additional, and Volkmer, Anne Kathrin, additional

Published
2022
Full Text
View/download PDF

32. Fehlbildungen: 6.1 Wissenschaftlicher Überblick: Brustdeformitäten

Author

Aktas, Bahriye, Banys-Paluchowski, Maggie, Ditsch, Nina, Aktas, B ( Bahriye ), Banys-Paluchowski, M ( Maggie ), Ditsch, N ( Nina ), Witzel, Isabell; https://orcid.org/0000-0002-8734-4521, Aktas, Bahriye, Banys-Paluchowski, Maggie, Ditsch, Nina, Aktas, B ( Bahriye ), Banys-Paluchowski, M ( Maggie ), Ditsch, N ( Nina ), and Witzel, Isabell; https://orcid.org/0000-0002-8734-4521

Published
2024

33. Zentrale Mastopexie

Author

Aktas, Bahriye, Banys-Paluchowski, Maggie, Ditsch, Nina, Aktas, B ( Bahriye ), Banys-Paluchowski, M ( Maggie ), Ditsch, N ( Nina ), Witzel, Isabell; https://orcid.org/0000-0002-8734-4521, Aktas, Bahriye, Banys-Paluchowski, Maggie, Ditsch, Nina, Aktas, B ( Bahriye ), Banys-Paluchowski, M ( Maggie ), Ditsch, N ( Nina ), and Witzel, Isabell; https://orcid.org/0000-0002-8734-4521

Published
2024

36. ASO Visual Abstract: Minimally-Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment—A New Concept

Author

Pfob, André, primary, Cai, Lie, additional, Schneeweiss, Andreas, additional, Rauch, Geraldine, additional, Thomas, Bettina, additional, Schaefgen, Benedikt, additional, Kuemmel, Sherko, additional, Reimer, Toralf, additional, Hahn, Markus, additional, Thill, Marc, additional, Blohmer, Jens-Uwe, additional, Hackmann, John, additional, Malter, Wolfram, additional, Bekes, Inga, additional, Friedrichs, Kay, additional, Wojcinski, Sebastian, additional, Joos, Sylvie, additional, Paepke, Stefan, additional, Degenhardt, Tom, additional, Rom, Joachim, additional, Rody, Achim, additional, van Mackelenbergh, Marion, additional, Banys-Paluchowski, Maggie, additional, Große, Regina, additional, Reinisch, Mattea, additional, Karsten, Maria Margarete, additional, Sidey-Gibbons, Chris, additional, Wallwiener, Markus, additional, Golatta, Michael, additional, and Heil, Joerg, additional

Published
2023
Full Text
View/download PDF

37. Seltene Malignome der Brust

Author

Pervan, Mascha, primary, Princk, Henriette, additional, Meneder, Sabine, additional, Banys-Paluchowski, Maggie, additional, Fehm, Tanja, additional, Ruckhäberle, Eugen, additional, Hanker, Lars, additional, Fitzgerald, Sophia, additional, Rody, Achim, additional, and Krawczyk, Natalia, additional

Published
2023
Full Text
View/download PDF

38. Update Mammakarzinom 2023 Teil 2 – Brustkrebs in fortgeschrittenen Krankheitsstadien

Author

Lux, Michael P., additional, Hartkopf, Andreas D., additional, Fehm, Tanja N., additional, Welslau, Manfred, additional, Müller, Volkmar, additional, Schütz, Florian, additional, Fasching, Peter A., additional, Janni, Wolfgang, additional, Witzel, Isabell, additional, Thomssen, Christoph, additional, Beierlein, Milena, additional, Belleville, Erik, additional, Untch, Michael, additional, Thill, Marc, additional, Tesch, Hans, additional, Ditsch, Nina, additional, Aktas, Bahriye, additional, Banys-Paluchowski, Maggie, additional, Kolberg-Liedtke, Cornelia, additional, Wöckel, Achim, additional, Kolberg, Hans-Christian, additional, Harbeck, Nadia, additional, Bartsch, Rupert, additional, Schneeweiss, Andreas, additional, Ettl, Johannes, additional, Würstlein, Rachel, additional, Krug, David, additional, Taran, Florin-Andrei, additional, Lüftner, Diana, additional, and Stickeler, Elmar, additional

Published
2023
Full Text
View/download PDF

39. Update Mammakarzinom 2023 Teil 3 – Expertenmeinungen zu Brustkrebs in frühen Krankheitsstadien

Author

Kolberg, Hans-Christian, additional, Hartkopf, Andreas D., additional, Fehm, Tanja N., additional, Welslau, Manfred, additional, Müller, Volkmar, additional, Schütz, Florian, additional, Fasching, Peter A., additional, Janni, Wolfgang, additional, Witzel, Isabell, additional, Thomssen, Christoph, additional, Beierlein, Milena, additional, Belleville, Erik, additional, Untch, Michael, additional, Thill, Marc, additional, Tesch, Hans, additional, Ditsch, Nina, additional, Lux, Michael P., additional, Aktas, Bahriye, additional, Banys-Paluchowski, Maggie, additional, Kolberg-Liedtke, Cornelia, additional, Wöckel, Achim, additional, Harbeck, Nadia, additional, Stickeler, Elmar, additional, Bartsch, Rupert, additional, Schneeweiss, Andreas, additional, Ettl, Johannes, additional, Krug, David, additional, Taran, Florin-Andrei, additional, Lüftner, Diana, additional, and Würstlein, Rachel, additional

Published
2023
Full Text
View/download PDF

45. Real de-escalation or escalation in disguise?

Author

Banys-Paluchowski, Maggie, Rubio, Isabel T., Ditsch, Nina, Krug, David, Gentilini, Oreste Davide, and Kühn, Thorsten

Subjects
Surgery, ddc:610, General Medicine
Abstract

The past two decades have seen an unprecedented trend towards de-escalation of surgical therapy in the setting of early BC, the most prominent examples being the reduction of re-excision rates for close surgical margins after breast-conserving surgery and replacing axillary lymph node dissection by less radical procedures such as sentinel lymph node biopsy (SLNB). Numerous studies confirmed that reducing the extent of surgery in the upfront surgery setting does not impact locoregional recurrences and overall outcome. In the setting of primary systemic treatment, there is an increased use of less invasive staging strategies reaching from SLNB and targeted lymph node biopsy (TLNB) to targeted axillary dissection (TAD). Omission of any axillary surgery in the presence of pathological complete response in the breast is currently being investigated in clinical trials. On the other hand, concerns have been raised that surgical de-escalation might induce an escalation of other treatment modalities such as radiation therapy. Since most trials on surgical de-escalation did not include standardized protocols for adjuvant radiotherapy, it remains unclear, whether the effect of surgical de-escalation was valid in itself or if radiotherapy compensated for the decreased surgical extent. Uncertainties in scientific evidence may therefore lead to escalation of radiotherapy in some settings of surgical de-escalation. Further, the increasing rate of mastectomies including contralateral procedures in patients without genetic risk is alarming. Future studies of locoregional treatment strategies need to include an interdisciplinary approach to integrate de-escalation approaches combining surgery and radiotherapy in a way that promotes optimal quality of life and shared decision-making.

Published
2023

46. Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy

Author

Montagna, Giacomo, Mrdutt, Mary M., Sun, Susie X., Hlavin, Callie, Diego, Emilia J., Wong, Stephanie M., Barrio, Andrea V., van den Bruele, Astrid Botty, Cabioglu, Neslihan, Sevilimedu, Varadan, Rosenberger, Laura H., Hwang, E. Shelley, Ingham, Abigail, Papassotiropoulos, Bärbel, Nguyen-Sträuli, Bich Doan, Kurzeder, Christian, Aybar, Danilo Díaz, Vorburger, Denise, Matlac, Dieter Michael, Ostapenko, Edvin, Riedel, Fabian, Fitzal, Florian, Meani, Francesco, Fick, Franziska, Sagasser, Jacqueline, Heil, Jörg, Karanlik, Hasan, Dedes, Konstantin J., Romics, Laszlo, Banys-Paluchowski, Maggie, Muslumanoglu, Mahmut, Perez, Maria Del Rosario Cueva, Díaz, Marcelo Chávez, Heidinger, Martin, Fehr, Mathias K., Reinisch, Mattea, Tukenmez, Mustafa, Maggi, Nadia, Rocco, Nicola, Ditsch, Nina, Gentilini, Oreste Davide, Paulinelli, Regis R., Zarhi, Sebastián Solé, Kuemmel, Sherko, Bruzas, Simona, di Lascio, Simona, Parissenti, Tamara K., Hoskin, Tanya L., Güth, Uwe, Ovalle, Valentina, Tausch, Christoph, Kuerer, Henry M., Caudle, Abigail S., Boileau, Jean-Francois, Boughey, Judy C., Kühn, Thorsten, Morrow, Monica, and Weber, Walter P.

Abstract

IMPORTANCE: Data on oncological outcomes after omission of axillary lymph node dissection (ALND) in patients with breast cancer that downstages from node positive to negative with neoadjuvant chemotherapy are sparse. Additionally, the best axillary surgical staging technique in this scenario is unknown. OBJECTIVE: To investigate oncological outcomes after sentinel lymph node biopsy (SLNB) with dual-tracer mapping or targeted axillary dissection (TAD), which combines SLNB with localization and retrieval of the clipped lymph node. DESIGN, SETTING, AND PARTICIPANTS: In this multicenter retrospective cohort study that was conducted at 25 centers in 11 countries, 1144 patients with consecutive stage II to III biopsy-proven node-positive breast cancer were included between April 2013 and December 2020. The cumulative incidence rates of axillary, locoregional, and any invasive (locoregional or distant) recurrence were determined by competing risk analysis. EXPOSURE: Omission of ALND after SLNB or TAD. MAIN OUTCOMES AND MEASURES: The primary end points were the 3-year and 5-year rates of any axillary recurrence. Secondary end points included locoregional recurrence, any invasive (locoregional and distant) recurrence, and the number of lymph nodes removed. RESULTS: A total of 1144 patients (median [IQR] age, 50 [41-59] years; 78 [6.8%] Asian, 105 [9.2%] Black, 102 [8.9%] Hispanic, and 816 [71.0%] White individuals; 666 SLNB [58.2%] and 478 TAD [41.8%]) were included. A total of 1060 patients (93%) had N1 disease, 619 (54%) had ERBB2 (formerly HER2)–positive illness, and 758 (66%) had a breast pathologic complete response. TAD patients were more likely to receive nodal radiation therapy (85% vs 78%; P = .01). The clipped node was successfully retrieved in 97% of TAD cases and 86% of SLNB cases (without localization). The mean (SD) number of sentinel lymph nodes retrieved was 3 (2) vs 4 (2) (P < .001), and the mean (SD) number of total lymph nodes removed was 3.95 (1.97) vs 4.44 (2.04) (P < .001) in the TAD and SLNB groups, respectively. The 5-year rates of any axillary, locoregional, and any invasive recurrence in the entire cohort were 1.0% (95% CI, 0.49%-2.0%), 2.7% (95% CI, 1.6%-4.1%), and 10% (95% CI, 8.3%-13%), respectively. The 3-year cumulative incidence of axillary recurrence did not differ between TAD and SLNB (0.5% vs 0.8%; P = .55). CONCLUSIONS AND RELEVANCE: The results of this cohort study showed that axillary recurrence was rare in this setting and was not significantly lower after TAD vs SLNB. These results support omission of ALND in this population.

Published
2024
Full Text
View/download PDF

47. Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024.

Author

Park-Simon, Tjoung-Won, Müller, Volkmar, Albert, Ute-Susann, Banys-Paluchowski, Maggie, Bauerfeind, Ingo, Blohmer, Jens-Uwe, Budach, Wilfried, Dall, Peter, Ditsch, Nina, Fallenberg, Eva M., Fasching, Peter A., Fehm, Tanja, Friedrich, Michael, Gerber, Bernd, Gluz, Oleg, Harbeck, Nadia, Hartkopf, Andreas Daniel, Heil, Jörg, Huober, Jens, and Jackisch, Christian

Subjects
BREAST tumor diagnosis, BREAST tumor prevention, ADENOCARCINOMA, BEHAVIOR modification, BREAST tumors, METASTASIS, ADJUVANT chemotherapy, HEALTH behavior, COMBINED modality therapy, EARLY diagnosis, COMMITTEES, GENETIC testing
Abstract

Introduction: Each year the interdisciplinary AGO (Arbeitsgemeinschaft Gynäkologische Onkologie, German Gynecological Oncology Group) Breast Committee on Diagnosis and Treatment of Breast Cancer provides updated state-of-the-art recommendations for early and metastatic breast cancer. Methods: The updated evidence-based treatment recommendations for early and metastatic breast cancer have been released in March 2024. Results and Conclusion: This paper concisely captures the updated recommendations for early breast cancer chapter by chapter. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024.

Author

Thill, Marc, Janni, Wolfgang, Albert, Ute-Susann, Banys-Paluchowski, Maggie, Bauerfeind, Ingo, Blohmer, Jens, Budach, Wilfried, Dall, Peter, Ditsch, Nina, Fallenberg, Eva Maria, Fasching, Peter A., Fehm, Tanja, Friedrich, Michael, Gerber, Bernd, Gluz, Oleg, Harbeck, Nadia, Hartkopf, Andreas, Heil, Jörg, Huober, Jens, and Jackisch, Christian

Subjects
BREAST cancer prognosis, BREAST tumor diagnosis, BREAST tumor treatment, GENOMICS, PALLIATIVE treatment, CANCER patients, METASTASIS, GENE expression, CANCER chemotherapy, BONE metastasis, COMBINED modality therapy, COMMITTEES
Abstract

The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents the 2024 update of the evidence-based recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. HER2-Positive Early Breast Cancer: Time for Ultimate De-Escalation?

Author

Tauber, Nikolas, Cirkel, Christoph, Claussen, Anna, Fick, Franziska, Kontomanolis, Emmanuel, Krawczyk, Natalia, Rody, Achim, and Banys-Paluchowski, Maggie

Subjects
THERAPEUTIC use of antineoplastic agents, THERAPEUTIC use of monoclonal antibodies, TRASTUZUMAB, PATIENT safety, BREAST tumors, EARLY detection of cancer, CANCER patient medical care, ESTROGEN receptors, CANCER chemotherapy, DISEASES, ONCOGENES, EPIDERMAL growth factor receptors
Abstract

Simple Summary: In the quest for de-escalation strategies, the complete elimination of non-targeted cytotoxic chemotherapy is often considered the ultimate goal in oncological therapy. This is particularly evident in HER2-positive breast cancer, where expanding targeted anti-HER2 therapy is a focal point of the current research due to the groundbreaking success achieved with trastuzumab. At present, several ongoing studies are examining chemotherapy-free regimens as part of initiatives to minimize the morbidity and toxic side effects of HER2-positive early breast cancer, while ensuring high oncogenic safety. Despite the promising early results achieved by these studies, the standard of care still entails combining anti-HER2 treatment with a chemotherapy backbone. De-escalation is currently taking place in both the surgical and systemic treatment of breast cancer. The introduction of trastuzumab, the first monoclonal antibody against the HER2 receptor, over 20 years ago was a milestone in the treatment of HER2-positive breast cancer and marked the beginning of a new era in targeted tumor therapy. In the sense of de-escalation, omitting non-targeted cytotoxic chemotherapy altogether is often hailed as the ultimate goal of oncological research. Especially in cases of small, node-negative, HER2-positive early breast cancer, it remains a challenge for clinicians to establish the safest and most efficient treatment plan while considering the significant potential for toxic side effects associated with chemotherapy and HER2-targeted therapy, and the generally excellent prognosis. In this context, several ongoing studies are currently assessing chemotherapy-free regimens as part of strategies aimed at de-escalating therapy in the field of HER2-positive early breast cancer. Despite the promising early results of these studies, the combination of anti-HER2 treatment with a chemotherapy backbone remains the standard of care. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. Systemische Therapie von prämenopausalen Patientinnen mit hormonrezeptorpositivem, HER2-negativem Brustkrebs in den Frühstadien – Kontroversen und Standards in der Krankenversorgung.

Author

Müller, Volkmar, Fasching, Peter A., Nabieva, Naiba, Fehm, Tanja N., Thill, Marc, Schmidt, Marcus, Kühn, Thorsten, Banys-Paluchowski, Maggie, Belleville, Erik, Juhasz-Böss, Ingolf, Untch, Michael, Kolberg, Hans-Christian, Harbeck, Nadia, Aktas, Bahriye, Stickeler, Elmar, Kreuzeder, Julia, Hartkopf, Andreas D., Janni, Wolfgang, and Ditsch, Nina

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results